Key result
PDE inhibitor combination therapy increases MDD treatment response odds ~377% versus SSRI monotherapy.
Why the study?
The use of phosphodiesterase inhibitors in the treatment of major depressive disorder remains unclear compared to SSRI monotherapy.
Does PDE inhibitor combination therapy improve treatment response rates in patients with major depressive disorder compared to SSRI monotherapy?
Meta-Analysis (n=270)
Does PDE inhibitor combination therapy improve treatment response rates in patients with major depressive disorder compared to SSRI monotherapy?
Odds Ratio: 4.77 (95% CI 2.05–11.12)
p-value: p=0.0003
The addition of a PDE inhibitor to SSRI therapy significantly improves short-term treatment response rates in patients with major depressive disorder compared to SSRI monotherapy alone.
PDE inhibitor addition to SSRIs may improve MDD response; extends RCT evidence for adjunctive strategies beyond monotherapy.
Selective serotonin reuptakeinhibitors (SSRIs) are the gold standard treatment for major depressive disorder (MDD). However, the use of phosphodiesterase (PDE) inhibitors in the treatment of MDD remains unclear. Our study aims to compare the effect of PDE inhibitor combination therapy to SSRI monotherapy for the treatment of MDD. We performed a comprehensive literature search using PubMed, EMBASE, and Web of Science databases, for studies that assess the impact of PDE inhibitor therapy on MDD patients. The primary outcome of our study was treatment response rate at the end of study time. Pooled odds ratio (OR) and corresponding 95% confidence intervals (CIs) were calculated using the random-effects model. A P -value <0.05 was considered statistically significant. A total of four randomized control trials (RCTs), including 270 patients with MDD, were included in the analysis. Follow-up periods ranged from 6 to 12 weeks. The PDE inhibitor group was associated with a significantly higher treatment response rate (OR, 4.77; 95% CI, 2.05-11.12; P = 0.0003). Our meta-analysis demonstrated that MDD patients receiving PDE inhibitor combination therapy had a higher treatment response rate than MDD patients receiving SSRI monotherapy. Further large-scale RCTs with long-term follow-ups are necessary to validate our findings.
No takes yet. Share an insight, caveat, or question.
Nawras et al. (2023) conducted a meta-analysis in Major depressive disorder (MDD) (n=270). Phosphodiesterase (PDE) inhibitor combination therapy vs. SSRI monotherapy was evaluated on treatment response rate at the end of study time (OR 4.77, 95% CI 2.05-11.12, p=0.0003). PDE inhibitor combination therapy significantly increased the treatment response rate compared to SSRI monotherapy in major depressive disorder (OR 4.77; 95% CI 2.05-11.12; P=0.0003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: